

1 ORIGINAL ARTICLE

2 **Development and Validation of Prediction Models for Sentinel**  
3 **Lymph Node Status Indicating Postmastectomy Radiotherapy in**  
4 **Breast Cancer: a Population-Based Study of 18 185 Women**

5 Miriam Svensson, MD<sup>1</sup>; Pär-Ola Bendahl, PhD<sup>2</sup>; Sara Alkner, MD, PhD<sup>3</sup>; Emma Hansson, MD, PhD<sup>4,5</sup>; Lisa  
6 Rydén, MD, PhD<sup>1,6</sup>; Looket Dihge, MD, PhD<sup>1,7\*</sup>

7 <sup>1</sup>Department of Clinical Sciences, Division of Surgery, Lund University, Lund, Sweden.

8 <sup>2</sup>Department of Clinical Sciences, Division of Oncology and Pathology, Lund University, Lund, Sweden.

9 <sup>3</sup>Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.

10 <sup>4</sup>Department of Plastic Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

11 <sup>5</sup>Region Västra Götaland, Sahlgrenska University Hospital, Department of Plastic Surgery, Gothenborg Sweden.

12 <sup>6</sup>Department of Surgery, Skåne University Hospital, Malmö, Sweden.

13 <sup>7</sup>Department of Plastic and Reconstructive Surgery, Skåne University Hospital, Malmö, Sweden.

14

15 \* Corresponding Author:

16 Looket Dihge,

17 Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Surgery, Medicon Village, SE-  
18 223 81, Lund, Sweden

19 Email: [looket.dihge@med.lu.se](mailto:looket.dihge@med.lu.se) Tel: +46 702556835

20

21 **Funding:** This study was funded by The Governmental Funding of Clinical Research within the  
22 National Health Service (ALF), Swedish Research Council, Erling Persson Foundation, and Per-Eric  
23 and Ulla Schyberg's Foundation. The funding sources had no role in the study design, analyses, data  
24 interpretation, writing of the manuscript, or the decision to submit the manuscript.

25

26 **Data Availability Statement:** The data sets generated and analyzed in the present study are  
27 available from the corresponding author upon reasonable request.

28

29 **Disclosure:** The authors have no conflicts of interest to declare.

30

31 **Key Words:** Breast Neoplasms; Sentinel Lymph Node; Radiotherapy; Breast Reconstruction;  
32 Nomograms; Clinical decision support.

33 **Abstract**

34 **Background:** Postmastectomy radiotherapy (PMRT) impairs the outcome of immediate breast  
35 reconstruction (IBR) in patients with breast cancer, and the sentinel lymph node (SLN) status  
36 is crucial in evaluating the need for PMRT. This study aimed to develop models to  
37 preoperatively predict the risk for SLN metastasis indicating the need for PMRT.

38 **Methods:** Women diagnosed with clinically node-negative (cN0) T1-T2 breast cancer from  
39 January 2014 to December 2017 were identified within the Swedish National Quality Register  
40 for Breast Cancer. Nomograms for nodal prediction based on preoperatively accessible patient  
41 and tumor characteristics were developed using adaptive LASSO logistic regression. The  
42 prediction of  $\geq 1$  and  $> 2$  SLN macrometastases (macro-SLNMs) adheres to the current  
43 guidelines on use of PMRT and reflects the exclusion criteria in ongoing clinical trials aiming  
44 to de-escalate locoregional radiotherapy in patients with 1-2 macro-SLNMs, respectively.  
45 Predictive performance was evaluated using area under the receiver operating characteristic  
46 curve (AUC) and calibration plots.

47 **Results:** Overall, 18 185 women were grouped into training ( $n = 13\ 656$ ) and validation ( $n =$   
48  $4529$ ) cohorts. The well-calibrated nomograms predicting  $\geq 1$  and  $> 2$  macro-SLNMs displayed  
49 AUCs of 0.708 and 0.740, respectively, upon validation. By using the nomogram for  $\geq 1$  macro-  
50 SLNMs, the risk could be updated from the pre-test population prevalence 13% to the post-test  
51 range 2%-75%.

52 **Conclusion:** Nomograms based on routine patient and tumor characteristics could be used for  
53 prediction of SLN status that would indicate PMRT need and assist the decision-making on  
54 IBR for patients with cN0 breast cancer.

## 55 **Introduction**

56 Breast reconstructive surgery improves the quality of life of patients with breast cancer  
57 undergoing mastectomy<sup>1, 2</sup>. According to international guidelines, all patients undergoing  
58 mastectomy should be counseled about reconstructive options. To evaluate the optimal timing  
59 and type of breast reconstruction, risk factors for postoperative complications must be  
60 considered, such as smoking<sup>3</sup>, obesity<sup>4</sup>, and diabetes<sup>5</sup>. Specifically, postmastectomy  
61 radiotherapy (PMRT) is recognized to impact outcomes in those receiving immediate breast  
62 reconstruction (IBR)<sup>6-10</sup>. Common complications involve capsular contracture and loss of  
63 implant following immediate implant-based reconstructions<sup>6, 7</sup>, while tissue necrosis is a  
64 common complication associated with immediate autologous reconstructions and PMRT<sup>11</sup>.  
65 Therefore, evaluation of the need for PMRT is essential to support patients with breast cancer  
66 and health-care providers in making informed decisions on breast reconstructive surgery and  
67 IBR in particular.

68 The decision on PMRT is based on axillary lymph node metastasis, tumor size of >50  
69 mm or involved resection margins<sup>12-14</sup>. Sentinel lymph node biopsy (SLNB) is the gold standard  
70 for axillary nodal staging in patients with clinically node-negative (cN0) invasive breast cancer,  
71 and all patients with  $\geq 1$  SLN macrometastases (macro-SLNMs) (>2.0 mm) receive PMRT,  
72 according to current guidelines<sup>12-14</sup>. Ongoing randomized clinical trials are examining the  
73 possibility of omitting locoregional radiotherapy in patients with 1–2 macro-SLNMs<sup>15-17</sup>.  
74 However, for those with a heavy nodal disease burden, PMRT remains advisable.  
75 Consequently, the identification of patients with >2 macro-SLNMs is crucial. A non-invasive  
76 tool for predicting SLN status could be beneficial in preoperatively identifying patients at risk  
77 of postoperative complications associated with the requirement for PMRT following IBR.  
78 Although there are several nomograms for predicting axillary node status<sup>18-20</sup>, most of them  
79 include variables that are not routinely available in a preoperative setting. Moreover, predictive

80 tools to identify patients with cN0 breast cancer at high risk of macro-SLNM indicating the  
81 need for PMRT, are still lacking.

82 This study aims to develop and validate nomograms for risk stratification of SLN  
83 metastasis indicating the need for PMRT in patients with cN0 breast cancer using only routine  
84 clinical patient and tumor characteristics. The primary endpoint is the prediction of  $\geq 1$  macro-  
85 SLNMs, according to current guidelines on the use of PMRT. The secondary endpoint is the  
86 prediction of  $>2$  macro-SLNMs that adhere to the exclusion criteria of ongoing randomized  
87 controlled trials aiming to de-escalate the use of locoregional radiotherapy in patients with low  
88 nodal metastatic burden. Adaptive LASSO logistic regression is used to minimize the risk of  
89 overfitting the models. To our knowledge, this is the first study to present nomograms that  
90 stratify the risk for SLNM, indicating the need for PMRT in patients with cN0 breast cancer.

## 91 **Methods**

### 92 *Study population*

93 This retrospective study was conducted using data from the Swedish National Quality  
94 Register for Breast Cancer (NKBC), a prospectively maintained, population-based register with  
95 almost 100% completeness when cross-linked to the Swedish Cancer Register<sup>21</sup>. All women  
96 diagnosed with invasive breast cancer in Sweden from January 2014 to December 2017,  
97 primarily treated with surgery, were identified. The exclusion criteria were: bilateral breast  
98 cancer, neoadjuvant chemotherapy, ductal carcinoma *in situ* (DCIS), tumor size  $>50$  mm or  
99 unknown tumor size, stage IV breast cancer, palpable axillary lymphadenopathy, absent or  
100 incongruent data on axillary nodal status and omission of SLNB. The dataset was split into a  
101 training cohort and a validation cohort. The training cohort comprised patients diagnosed in  
102 2014-2016, while the remaining patients constituted the temporal validation cohort.

103 For all included patients, SLNB was the primary axillary staging procedure for evaluation  
104 of axillary nodal status, and nodal metastases were categorized into macrometastases if a  
105 metastatic deposit  $>2.0$  mm was displayed<sup>22</sup>. For the prediction of  $>2$  macro-SLNs, patients  
106 with macrometastases in at least two sentinel nodes and with any additional lymph node  
107 metastasis identified by SLNB or by completion axillary lymph node dissection, were included.

108 This research was performed in accordance with the Declaration of Helsinki and followed  
109 the STROBE and TRIPOD guidelines for reporting observational studies<sup>23, 24</sup>. The study was  
110 approved by the Swedish Ethical Review Authority (2019–02139). Written informed consent  
111 for participation was not required for this register-based study in accordance with the national  
112 legislation and institutional requirements. The study was registered in the ISRCTN database  
113 (ISRCTN 14341750).

#### 114 *Clinicopathological predictors*

115 Based on previous studies on variables associated with SLN status<sup>25, 26</sup>, the following  
116 candidate predictors were evaluated: age at diagnosis, tumor size, Nottingham histological  
117 grade, histological type, estrogen receptor (ER) status, progesterone receptor (PR) status,  
118 amplification of human epidermal growth factor receptor 2 (HER2), and multifocality. Patient  
119 age has been reported to have a non-linear association with nodal status, with the lowest  
120 prevalence of lymphatic involvement for those around 70 years<sup>27</sup>. Therefore, patients were  
121 categorized into the following age groups:  $\leq 65$ , 66–75 and  $>75$  years. Multifocality was defined  
122 as the presence of  $\geq 2$  foci of invasive breast cancer within the same breast separated by benign  
123 tissue on the histological examination of the excised section<sup>28</sup>, and tumor size was defined as  
124 the greatest dimension of the largest invasive focus. For ER and PR status,  $\geq 1\%$  stained nuclei  
125 by immunohistochemistry (IHC) were considered positive according to the definitions of the  
126 European Society for Medical Oncology (ESMO)<sup>12</sup>. To evaluate HER2 status, IHC and *in situ*  
127 hybridization (ISH) were performed, and tumors with IHC 3+ scoring and/or positive ISH-test

128 were regarded as HER2-positive. The histological type was categorized into three groups:  
129 invasive carcinoma of no special type (NST), invasive lobular carcinoma (ILC), and other  
130 invasive carcinoma. Mixed types were excluded from the analyzes.

### 131 *Statistical analysis*

132 Univariable logistic regression analysis was used to explore the unadjusted associations  
133 between each candidate predictor and the two endpoints in the training cohort. Adaptive  
134 LASSO logistic regression<sup>29</sup> was then applied to select the most important predictors. LASSO  
135 regression is a commonly used machine learning technique for variable selection and model  
136 development, minimizing the risk of overfitting by forcing the absolute sizes of the regression  
137 coefficients of the standardized predictors to be bounded by a penalty factor,  $\lambda$ . The adaptive  
138 form of LASSO leads to even more parsimonious models than the standard LASSO<sup>30,31</sup>. To  
139 determine the optimal value of  $\lambda$ , we used 10-fold cross-validation in the training cohort. Cases  
140 with missing values for  $\geq 1$  candidate predictors were removed from the analyses. Two  
141 nomograms for predicting  $\geq 1$  and  $> 2$  macro-SLNMs, respectively, were developed based on  
142 the results from the adaptive LASSO regression analyses.

143 To evaluate each nomogram's discriminatory ability, the area under the receiver operating  
144 characteristic (ROC) curve (AUC) was calculated in the development and validation cohorts.  
145 Model accuracy was assessed in the validation cohort using calibration plots (graphical) and  
146 calibration slope and intercept (numerical). For comparison purposes, corresponding prediction  
147 models based on backward stepwise regression with uniform bootstrap-based shrinkage<sup>32</sup> were  
148 developed and are provided in the supplementary section (Supplemental Methods). All analyses  
149 were performed using STATA (StataCorp. 2021. *Stata Statistical Software: Release 17*.  
150 College Station, TX: StataCorp LLC).

## 151 **Results**

### 152 *Patient and tumor characteristics*

153 From January 2014 to December 2017, 23 256 breast cancer tumors, primarily treated  
154 with surgery, were registered in NKBC (Fig. S1). The final study cohort consisted of 18 185  
155 patients with breast cancer who met the eligibility criteria. Of these, 13 656 were diagnosed  
156 between 2014 and 2016, constituting the training cohort, and 4529 were diagnosed in 2017,  
157 constituting the temporal validation cohort. Patient and tumor characteristics of the training and  
158 validation cohorts were comparable (Table 1). Overall, 2409 patients (13%) displayed  $\geq 1$   
159 macro-SLNMs, and 278 (2%) displayed  $> 2$  macro-SLNMs. The overall median age at diagnosis  
160 was 64 years, and the median tumor size was 15 mm. Most patients displayed unifocal, hormone  
161 receptor-positive, HER2-negative, grade II carcinoma of NST.

### 162 *Variable selection and prediction model development using adaptive logistic LASSO regression*

163 The results from the univariable logistic regression analyses are presented in Table S1.  
164 Only patients with complete information on all candidate predictors were included in the  
165 adaptive LASSO logistic regression analyses ( $n = 12\ 168$ , 89%). Patient and tumor  
166 characteristics of those included in the analyses and those removed due to any missing value of  
167 the candidate predictors are presented in Table S2. For prediction of  $\geq 1$  macro-SLNMs, the  
168 adaptive LASSO regression-based prediction model identified patient age, tumor size,  
169 multifocality, histological type, histological grade, ER, PR, and HER2 status as predictors.  
170 Tumor size emerged as the most important predictor, followed by multifocality (Fig. S2a and  
171 S2b).

172 For the prediction of  $> 2$  macro-SLNMs, adaptive LASSO regression identified the  
173 following predictors: tumor size, histological grade, multifocality, patient age ( $> 65$  years vs.

174  $\leq 65$  years), and histological type (ILC *vs.* NST or others) (Fig. S2c and S2d). Tumor size was  
175 also the strongest predictor in this model.

176 The regression coefficients from the two adaptive LASSO regression analyses are  
177 presented in Table 2. Penalization of the coefficients was applied to minimize the risk of  
178 overfitting. Along with the estimated intercept, these coefficients constitute the function used  
179 for outcome prediction. A positive coefficient indicates that the variable increases the predicted  
180 probability, and a negative coefficient indicates that the variable decreases the predicted  
181 probability. The retained predictors and their corresponding regression coefficients in the two  
182 supplementary prediction models based on backward stepwise regression with bootstrap  
183 uniform shrinkage are presented in Supplemental Results and Table S3.

#### 184 *Nomogram development*

185 The results from the adaptive LASSO logistic regression analyses were used to develop  
186 Nomograms I and II, predicting  $\geq 1$  and  $> 2$  macro-SLNMs, respectively (Fig. 1). The penalized  
187 regression coefficients were transformed into specific scores on scales ranging from 0 to 10.  
188 By summarizing all scores in one nomogram, the patient's total score can be applied to a  
189 separate scale to predict the presence of  $\geq 1$  macro-SLNMs and  $> 2$  macro-SLNMs, respectively.

#### 190 *Prediction model performance*

191 The ROC curves and calibration plots illustrating the discriminatory ability and the  
192 accuracy of the two prediction models in the validation cohort are presented in Fig. 2. For  
193 Nomogram I, the AUC value was 0.720 (95% confidence interval CI, 0.707–0.733) in the  
194 training cohort and 0.708 (0.684–0.731) in the validation cohort, respectively. As illustrated by  
195 the calibration plot, the nomogram displayed good agreement between the predicted and  
196 observed prevalence of macro-SLNM in the validation cohort. The calibration slope and  
197 intercept were estimated to be 1.030 and -0.108, respectively. These estimates are close to the

198 optimal values, which are 1.000 and 0.000, respectively. When applying the nomogram to the  
199 overall study cohort, the individually predicted probability of  $\geq 1$  macro-SLNMs ranged from  
200 2% for some low-risk patients up to 75% for some high-risk patients (Fig. 3).

201 For Nomogram II, the AUC values in the training and validation cohorts were 0.775  
202 (0.743–0.807) and 0.740 (0.682–0.799), respectively (Fig. 2b). Similarly, this nomogram was  
203 well-calibrated with close approximation between the observed prevalence and predicted  
204 probability in the validation cohort (Fig. 2d), with a calibration slope and intercept of 0.984 and  
205 0.200, respectively. The individually predicted probability of  $>2$  macro-SLNMs ranged from  
206  $<1\%$  to 21% in the overall study cohort, with a mean of 2%. AUC values and model calibration  
207 for the two supplementary models based on logistic regression are presented in Supplemental  
208 results and Fig. S3.

## 209 Discussion

210 This study presents nomograms based on routine clinical patient and tumor characteristics  
211 for preoperative risk stratification of macro-SLNM indicating the need for PMRT. The chosen  
212 endpoints are according to the current guidelines on the use of PMRT and reflect ongoing  
213 clinical trials aiming to de-escalate locoregional irradiation in patients with low nodal  
214 metastatic burden. The nomograms displayed good discriminative ability, were well-calibrated,  
215 and could be used to increase or decrease the preoperative likelihood of macro-SLNM. For  
216 some high-risk patients, the estimated risk of  $\geq 1$  macro-SLNMs increased from the study  
217 population prevalence of 13% to 75% when using Nomogram I, while for others, the estimated  
218 risk decreased to 2%. This way, the nomograms can assist patients with breast cancer and  
219 health-care providers in making informed decisions regarding reconstructive surgery.

220 To evaluate nodal status indicating the need for PMRT before a decision on IBR,  
221 intraoperative SLN staging was previously performed using imprint cytology or frozen  
222 sections<sup>33</sup>. However, besides being time-consuming, intraoperative evaluation of the SLN status

223 inevitably leaves the patient with some degree of preoperative uncertainty regarding the nodal  
224 status and suitability of IBR. Additionally, it complicates surgical planning, impacting the  
225 required time in the operating theatre and the necessary intraoperative resources. Several studies  
226 suggested a staged SLNB procedure prior to mastectomy when IBR is planned<sup>34-36</sup>. While  
227 enabling a complete pathological evaluation of the SLN status before breast surgery, this  
228 strategy comes with the drawback of a two-step surgical procedure, including increased risk for  
229 infections, delay in definitive surgery, and increased arm morbidity and hospital costs<sup>37, 38</sup>.  
230 Moreover, the prevalence of lymphatic metastasis at the time of diagnosis is declining<sup>39</sup>, and  
231 the number of patients benefitting from an altered treatment plan due to surgically verified  
232 macro-SLNM and the need for PMRT is limited<sup>40</sup>. Therefore, a complementary, non-invasive  
233 prediction tool would be beneficial to preoperatively identify patients for whom IBR is  
234 associated with a high risk of postoperative complications due to nodal macrometastasis and  
235 PMRT. Ultimately, evaluating the risk factors impairing the outcome of IBR, including the  
236 need for PMRT, is essential to support breast cancer patients and healthcare providers to make  
237 informed decisions on breast reconstructive options.

238 In this study, we present two nomograms for preoperative prediction of SLN status  
239 indicating the need for PMRT based on routinely accessible clinicopathological characteristics.  
240 The nomograms were well-calibrated and displayed AUC values of 0.708 and 0.740 in the  
241 temporal validation cohort. For the prediction of axillary nodal status in cN0 breast cancer, the  
242 Memorial Sloan Kettering Cancer Center (MSKCC) nomogram<sup>18</sup> is one of the most frequently  
243 used, with an AUC of 0.754. However, this nomogram includes lymphovascular invasion,  
244 which is difficult to obtain in a preoperative setting<sup>41</sup>. Similar to most other nomograms for the  
245 prediction of axillary nodal status, it does not consider the size of the metastatic deposit.  
246 Previous trials have failed to prove any benefit of PMRT for patients with only micrometastatic  
247 deposit ( $\leq 2.0$  mm)<sup>42, 43</sup> and micrometastatic disease is not included in the current guidelines

248 concerning recommendations for PMRT<sup>12-14</sup>. Therefore, the presented Nomogram I was  
249 developed to predict  $\geq 1$  macro-SLNMs specifically. The endpoint of the second nomogram was  
250 chosen to adhere to the protocols of ongoing randomized clinical trials questioning the benefit  
251 of locoregional radiotherapy for patients with low nodal metastatic burden and verified 1-2  
252 macro-SLNMs. In the POSNOC trial<sup>16</sup>, women with T1-T2 tumors and 1-2 macro-SLNMs are  
253 randomized to no further axillary treatment vs. regional radiotherapy/axillary dissection.  
254 Similarly, the MA.39<sup>17</sup> and the T-REX<sup>15</sup> trials investigate the need for regional lymph node  
255 radiotherapy in patients with 1-2 macro-SLNMs; however, these trials are limited to patients  
256 with ER-positive, HER2-negative breast cancer. Since radiotherapy is associated with an  
257 increased risk of arm lymphedema<sup>44</sup>, postmastectomy pain syndrome<sup>45</sup>, and cardiopulmonary  
258 disease<sup>46, 47</sup>, a de-escalation of locoregional radiotherapy would not only improve the outcomes  
259 of IBR but also reduce morbidity and non-breast cancer mortality for these patients. Clinical  
260 guidelines concerning recommendations for PMRT will need to be revised if the omission of  
261 locoregional radiotherapy proves to be non-inferior in these patients, and the importance of  
262 identifying metastasis limited to 1-2 macro-SLNMs will be diminished. To our knowledge, the  
263 presented Nomogram II is the first nomogram to predict  $>2$  macro-SLNMs in patients with  
264 breast cancer for whom PMRT will remain recommended.

265 Adaptive LASSO regression was used to develop the nomograms. Although the LASSO  
266 algorithm has proved to be advantageous in the development of prediction models<sup>48, 49</sup>, the  
267 adaptive LASSO regression-based nomograms presented in this study did not outperform the  
268 prediction models based on backward stepwise regression with bootstrap uniform shrinkage  
269 presented in Supplementary material. Moreover, the different algorithms showed only small  
270 differences in variable selection. This observation is most likely due to the restricted number of  
271 candidate variables recognized as key predictors, and thus, the advantages offered by the  
272 adaptive LASSO algorithm were limited.

273 This study has some limitations. Besides its retrospective nature, all data were obtained  
274 from a quality register with incomplete data for some clinicopathological characteristics.  
275 However, NKBC is a national, population-based register with high completeness when cross-  
276 linked to the Swedish Cancer Register<sup>21</sup>, and good concordance when validated by re-extraction  
277 from medical records<sup>50</sup>. Moreover, although many patients were removed from the modeling  
278 due to missing data on one or more of the candidate variables, the study still included a large  
279 number of observations ( $n = 18\ 185$ ). Furthermore, this study is limited by the imbalanced  
280 distribution of macro-SLNM and >2 macro-SLNMs in the overall study cohort. Nevertheless,  
281 this is an important observation, highlighting the small number of patients benefitting from an  
282 altered treatment planning due to pathologically verified macro-SLNM and the need for PMRT.  
283 A strength of this study is the temporal validation of the nomograms regarding both  
284 discriminatory ability and model calibration. Although only variables that could be obtained in  
285 a preoperative setting were included as predictors for nodal disease, the included tumor  
286 characteristics were based on the definitive pathology result. Core needle biopsy has been  
287 shown to accurately evaluate the histological type and grade, hormone receptor status, and  
288 HER2 receptor status<sup>41</sup>; however, the differences between pre- and postoperative values are to  
289 be expected. Additionally, mammography may over- or underestimate the pathological tumor  
290 size<sup>51</sup> and the presence of multifocality<sup>52</sup>. The results should, therefore, be interpreted with  
291 caution. To enable the clinical application of these nomograms, a prospective validation study  
292 is necessary. Moreover, it must be noted that the nomogram does not consider other risk factors  
293 for postoperative complications of breast reconstructive surgery, such as obesity, smoking, and  
294 diabetes.

295 In conclusion, this study presents nomograms based on routine clinical patient and tumor  
296 characteristics for preoperative risk stratification of SLN status indicating the need for PMRT,  
297 addressing both current guidelines on the use of PMRT and ongoing clinical trials aiming to

298 de-escalate irradiation. The nomograms could be valuable in preoperatively evaluating the risks  
299 and benefits of IBR regarding the need for PMRT, thus supporting individualized decision-  
300 making on breast reconstructive surgery.

301 **Figure Legends**

302 **Figure 1. Nomograms predicting sentinel lymph node (SLN) status indicating the need for**  
303 **postmastectomy radiotherapy (PMRT): (a) probability of  $\geq 1$  SLN macrometastases (macro-**  
304 **SLNMs) according to current guidelines on use of PMRT; and (b) probability of  $>2$  macro-**  
305 **SLNMs according to endpoints of ongoing clinical trials aiming to de-escalate the use of**  
306 **irradiation.**

307 *HER2*, human epidermal growth factor receptor 2; *PR*, progesterone receptor; *ER*, estrogen  
308 receptor; *ILC*, invasive lobular carcinoma; *NST*, ductal carcinoma of no special type.

309 **Figure 2. Performance of the nomograms in the temporal validation cohort.** Receiver  
310 operating characteristic (ROC) curves representing the discriminatory ability for (a) Nomogram  
311 I, predicting  $\geq 1$  sentinel lymph node macrometastases (macro-SLNMs), and (b) Nomogram II,  
312 predicting  $>2$  macro-SLNMs. The Calibration plots illustrating the agreement between the  
313 observed prevalence and the predicted probability of (c)  $\geq 1$  macro-SLNMs and (d)  $>2$  macro-  
314 SLNMs, respectively, show good calibration, i.e., the predictions are not systematically biased.  
315 *AUC*, area under the curve.

316 **Figure 3. Individual predictions of  $\geq 1$  and  $>2$  sentinel lymph node macrometastases**  
317 **(macro-SLNMs) when applying the nomograms to the overall study cohort. (a) For**  
318 **Nomogram I, the predicted probability of  $\geq 1$  macro-SLNMs ranged from 2% for some low-risk**  
319 **patients up to 75% for some high-risk patients. (b) Likewise, the predicted probability of  $>2$**   
320 **macro-SLNMs ranged from  $<1\%$  to 21% when applying Nomogram II to each patient in the**  
321 **overall study cohort.**

322 **TABLES**

323 **Table 1. Patient and tumor characteristics of the training and validation cohorts**

<b>Variable</b>	<b>All n = 18 185</b>	<b>Training cohort n = 13 656</b>	<b>Validation cohort n = 4529</b>
<b>Age</b> (years), median (range)	64 (22-95)	64 (23-95)	65 (22-95)
Missing	0	0	0
<b>Patient age</b> , categories			
≤65 years	9686 (53)	7320 (53)	2366 (52)
66-75 years	6220 (34)	4626 (34)	1594 (35)
>75 years	2279 (13)	1710 (13)	569 (13)
Missing	0	0	0
<b>Tumor size</b> (mm), median (range)	15 (1-50)	15 (1-50)	15 (1-50)
Missing	0	0	0
<b>Histological type</b>			
NST	13 979 (79)	10 511 (79)	3468 (80)
ILC	2320 (13)	1779 (13)	541 (12)
Others	1315 (7)	977 (7)	338 (8)
Missing	571	389	182
<b>Nottingham histological grade</b>			
I	4068 (23)	3081 (23)	987 (22)
II	9447 (53)	7118 (53)	2329 (52)
III	4467 (25)	3298 (24)	1169 (26)
Missing	203	159	44
<b>Multifocality</b>			
Yes	2924 (16)	2167 (16)	757 (17)
No	15 229 (84)	11 463 (84)	3766 (83)
Missing	32	26	6
<b>ER status</b>			
Positive	16 068 (92)	12 032 (92)	1036 (91)
Negative	1432 (8)	1028 (8)	404 (9)
Missing	685	596	89
<b>PR status</b>			
Positive	14 637 (85)	10 988 (86)	3649 (83)
Negative	2596 (15)	1844 (14)	752 (17)
Missing	952	824	128
<b>HER2 status</b>			
Positive	2009 (11)	1497 (11)	512 (11)
Negative	15 917 (89)	11 939 (89)	3978 (89)
Missing	259	220	39
<b>Ki67</b> (%), median (range)	20 (0-100)	20 (0-100)	20 (1-100)
Missing	131	98	33
<b>≥1 macro-SLNMs</b>			
Yes	2409 (13)	1852 (14)	557 (12)
No	15 776 (87)	11 804 (86)	3972 (88)
Missing	0	0	0
<b>&gt;2 macro-SLNMs</b>			
Yes	278 (2)	203 (1)	75 (2)
No	17 907 (98)	13 453 (99)	4454 (98)
Missing	0	0	0

324 Values in parentheses are valid percentages of each column if not otherwise explained. The  
325 percentage values are rounded, and the total percentage may therefore not be 100.

- 326 *NST*, no special type; *ILC*, invasive lobular carcinoma; *ER*, estrogen receptor; *PR*,
- 327 progesterone receptor; *HER2*, human epidermal growth factor receptor 2; *macro-SLNMs*,
- 328 sentinel lymph node macrometastases.

329 **Table 2. Penalized regression coefficients for prediction of  $\geq 1$  and  $> 2$  sentinel lymph**  
 330 **node macrometastases (macro-SLNMs) identified by adaptive LASSO regression ( $n = 12$**   
 331 **168)**

Variable	Prediction of $\geq 1$ macro-SLNMs Penalized coefficients	Prediction of $> 2$ macro-SLNMs Penalized coefficients
<b>Age (years)</b>		
$\leq 65$	0 (reference)	
66-75	-0.276	
$> 75$	-0.128	
<b>Age (years) (<math>&gt; 65</math> vs. <math>\leq 65</math>)</b>		-0.171
<b>Tumor size (mm)</b>	0.068	0.076
<b>Histological type</b>		
NST	0 (reference)	
ILC	-0.270	
Others	-0.658	
<b>Histological type (ILC vs. NST or others)</b>		0.070
<b>Histological grade</b>		
I	0 (reference)	0 (reference)
II	0.359	0.743
III	0.489	0.813
<b>Multifocality (multifocal vs. unifocal)</b>	0.643	0.489
<b>ER status (pos vs. neg)</b>	0.225	
<b>PR status (pos vs. neg)</b>	0.122	
<b>HER2 status (pos vs. neg)</b>	-0.078	
<b>Constant</b>	-3.669	-6.451

332 Binary coding was used for categorical variables with two levels and two binary so-called  
 333 dummy variables for categorical variables with three levels.

334 *NST*, ductal carcinoma of no special type; *ILC*, invasive lobular carcinoma; *ER*, estrogen  
 335 receptor; *PR*, progesterone receptor; *HER2*, human epidermal growth factor receptor 2.

336 **REFERENCES**

- 337 1. Dauplat J, Kwiatkowski F, Rouanet P, et al. Quality of life after mastectomy with or without  
338 immediate breast reconstruction. *Br J Surg*. 2017;104(9):1197-206.
- 339 2. Archangelo SCV, Sabino Neto M, Veiga DF, Garcia EB, Ferreira LM. Sexuality, depression  
340 and body image after breast reconstruction. *Clinics (Sao Paulo)*. 2019;74:e883.
- 341 3. Padubidri AN, Yetman R, Browne E, et al. Complications of postmastectomy breast  
342 reconstructions in smokers, ex-smokers, and nonsmokers. *Plast Reconstr Surg*.  
343 2001;107(2):342-9; discussion 50-1.
- 344 4. Fischer JP, Nelson JA, Kovach SJ, Serletti JM, Wu LC, Kanchwala S. Impact of obesity on  
345 outcomes in breast reconstruction: analysis of 15,937 patients from the ACS-NSQIP datasets.  
346 *J Am Coll Surg*. 2013;217(4):656-64.
- 347 5. Mortada H, Alwadai A, Bamakhrama B, et al. The Impact of Diabetes Mellitus on Breast  
348 Reconstruction Outcomes and Complications: A Systematic Literature Review and Meta-  
349 analysis. *Aesthetic Plast Surg*. 2023.
- 350 6. Barry M, Kell MR. Radiotherapy and breast reconstruction: a meta-analysis. *Breast Cancer*  
351 *Res Treat*. 2011;127(1):15-22.
- 352 7. de Boniface J, Coudé Adam H, Frisell A, et al. Long-term outcomes of implant-based  
353 immediate breast reconstruction with and without radiotherapy: a population-based study. *Br J*  
354 *Surg*. 2022;109(11):1107-15.
- 355 8. Jagsi R, Momoh AO, Qi J, et al. Impact of Radiotherapy on Complications and Patient-  
356 Reported Outcomes After Breast Reconstruction. *J Natl Cancer Inst*. 2018;110(2):157-65.
- 357 9. Shumway DA, Momoh AO, Sabel MS, Jagsi R. Integration of Breast Reconstruction and  
358 Postmastectomy Radiotherapy. *J Clin Oncol*. 2020;38(20):2329-40.
- 359 10. Heller DR, Zhuo H, Zhang Y, et al. Surgical Outcomes of Mastectomy with Immediate  
360 Autologous Reconstruction Followed by Radiation. *Ann Surg Oncol*. 2021;28(4):2169-79.

- 361 11. Liew B, Southall C, Kanapathy M, Nikkhah D. Does post-mastectomy radiation therapy  
362 worsen outcomes in immediate autologous breast flap reconstruction? A systematic review  
363 and meta-analysis. *J Plast Reconstr Aesthet Surg*. 2021;74(12):3260-80.
- 364 12. Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice  
365 Guidelines for diagnosis, treatment and follow-up†. *Ann Oncol*. 2019;30(8):1194-220.
- 366 13. Gradishar WJ, Moran MS, Abraham J, et al. Breast Cancer, Version 3.2022, NCCN Clinical  
367 Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2022;20(6):691-722.
- 368 14. Recht A, Comen EA, Fine RE, et al. Postmastectomy Radiotherapy: An American Society of  
369 Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical  
370 Oncology Focused Guideline Update. *Pract Radiat Oncol*. 2016;6(6):e219-e34.
- 371 15. Alkner S, de Boniface J, Lundstedt D, et al. Protocol for the T-REX-trial: tailored regional  
372 external beam radiotherapy in clinically node-negative breast cancer patients with 1-2 sentinel  
373 node macrometastases - an open, multicentre, randomised non-inferiority phase 3 trial. *BMJ*  
374 *Open*. 2023;13(9):e075543.
- 375 16. Goyal A, Mann GB, Fallowfield L, et al. POSNOC-POSitive Sentinel NOde: adjuvant therapy  
376 alone versus adjuvant therapy plus Clearance or axillary radiotherapy: a randomised  
377 controlled trial of axillary treatment in women with early-stage breast cancer who have  
378 metastases in one or two sentinel nodes. *BMJ Open*. 2021;11(12):e054365.
- 379 17. Parulekar WR, Berrang T, Kong I, et al. Cctg MA.39 tailor RT: A randomized trial of regional  
380 radiotherapy in biomarker low-risk node-positive breast cancer (NCT03488693). *Journal of*  
381 *Clinical Oncology*. 2019;37(15\_suppl):TPS602-TPS.
- 382 18. Bevilacqua JL, Kattan MW, Fey JV, Cody HS, 3rd, Borgen PI, Van Zee KJ. Doctor, what are  
383 my chances of having a positive sentinel node? A validated nomogram for risk estimation. *J*  
384 *Clin Oncol*. 2007;25(24):3670-9.
- 385 19. Meretoja TJ, Heikkilä PS, Mansfield AS, et al. A predictive tool to estimate the risk of axillary  
386 metastases in breast cancer patients with negative axillary ultrasound. *Ann Surg Oncol*.  
387 2014;21(7):2229-36.

- 388 20. Geng SK, Fu SM, Zhang HW, Fu YP. Predictive nomogram based on serum tumor markers  
389 and clinicopathological features for stratifying lymph node metastasis in breast cancer. BMC  
390 Cancer. 2022;22(1):1328.
- 391 21. Swedish National Quality Registry for Breast Cancer 2021 [cited 19 Jan 2023]. Available  
392 from: <https://cancercentrum.se/samverkan/cancerdiagnoser/brost/kvalitetsregister/>.
- 393 22. Edge S. AJCC Cancer Staging Manual, Eight Edition. New York: Springer; 2017.
- 394 23. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The  
395 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement:  
396 guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495-9.
- 397 24. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent Reporting of a multivariable  
398 prediction model for Individual Prognosis Or Diagnosis (TRIPOD): the TRIPOD Statement.  
399 Br J Surg. 2015;102(3):148-58.
- 400 25. Viale G, Zurrada S, Maiorano E, et al. Predicting the status of axillary sentinel lymph nodes in  
401 4351 patients with invasive breast carcinoma treated in a single institution. Cancer.  
402 2005;103(3):492-500.
- 403 26. Farley C, Bassett R, Meric-Bernstam F, et al. To Dissect or Not to Dissect: Can We Predict  
404 the Presence of Four or More Axillary Lymph Node Metastases in Postmenopausal Women  
405 with Clinically Node-Negative Breast Cancer? Ann Surg Oncol. 2023;30(13):8327-34.
- 406 27. Wildiers H, Van Calster B, van de Poll-Franse LV, et al. Relationship between age and  
407 axillary lymph node involvement in women with breast cancer. J Clin Oncol.  
408 2009;27(18):2931-7.
- 409 28. Hartman J, Ehinger A, Kovács A, et al. [Kvalitetsbilaga för Bröstpatologi (KVASt)] 2022  
410 [cited 5 Apr 2023]. Available from:  
411 <https://kunskapsbanken.cancercentrum.se/diagnoser/brostcancer/vardprogram/kvalitetsdokument-for--patologi/#chapter--Forfattare-KVASt-gruppen-for-brostpatologi>.  
412
- 413 29. Shortreed SM, Ertefaie A. Outcome-adaptive lasso: Variable selection for causal inference.  
414 Biometrics. 2017;73(4):1111-22.


- 415 30. Tibshirani R. Regression Shrinkage and Selection via the Lasso. *Journal of the Royal*  
416 *Statistical Society Series B (Methodological)*. 1996;58(1):267-88.
- 417 31. Tibshirani R. The lasso method for variable selection in the Cox model. *Stat Med*.  
418 1997;16(4):385-95.
- 419 32. Fernandez-Felix BM, García-Esquinas E, Muriel A, Royuela A, Zamora J. Bootstrap internal  
420 validation command for predictive logistic regression models. *The Stata Journal*.  
421 2021;21(2):498-509.
- 422 33. Wood BC, Levine EA, Marks MW, David LR. Outcomes of immediate breast reconstruction  
423 in patients undergoing single-stage sentinel lymph node biopsy and mastectomy. *Ann Plast*  
424 *Surg*. 2011;66(5):564-7.
- 425 34. Teven C, Agarwal S, Jaskowiak N, et al. Pre-mastectomy sentinel lymph node biopsy: a  
426 strategy to enhance outcomes in immediate breast reconstruction. *Breast J*. 2013;19(5):496-  
427 503.
- 428 35. McGuire K, Rosenberg AL, Showalter S, Brill KL, Copit S. Timing of sentinel lymph node  
429 biopsy and reconstruction for patients undergoing mastectomy. *Ann Plast Surg*.  
430 2007;59(4):359-63.
- 431 36. Klauber-Demore N, Calvo BF, Hultman CS, et al. Staged sentinel lymph node biopsy before  
432 mastectomy facilitates surgical planning for breast cancer patients. *Am J Surg*.  
433 2005;190(4):595-7.
- 434 37. Husen M, Paaschburg B, Flyger HL. Two-step axillary operation increases risk of arm  
435 morbidity in breast cancer patients. *Breast*. 2006;15(5):620-8.
- 436 38. Rönkä R, Smitten K, Sintonen H, et al. The impact of sentinel node biopsy and axillary  
437 staging strategy on hospital costs. *Ann Oncol*. 2004;15(1):88-94.
- 438 39. Tabar L, Chen TH, Yen AM, et al. Effect of Mammography Screening on Mortality by  
439 Histological Grade. *Cancer Epidemiol Biomarkers Prev*. 2018;27(2):154-7.
- 440 40. Svensson M, Dihge L. The Role of Surgical Axillary Staging Prior to Immediate Breast  
441 Reconstruction in the Era of De-Escalation of Axillary Management in Early Breast Cancer. *J*  
442 *Pers Med*. 2022;12(8).

- 443 41. Rakha EA, Ellis IO. An overview of assessment of prognostic and predictive factors in breast  
444 cancer needle core biopsy specimens. *J Clin Pathol.* 2007;60(12):1300-6.
- 445 42. Luo H, Yang OO, He JL, Lan T. Impact of Post-Mastectomy Radiation Therapy for Sentinel  
446 Lymph Node Micrometastases in Early-Stage Breast Cancer Patients. *Med Sci Monit.*  
447 2022;28:e933275.
- 448 43. Mamtani A, Patil S, Stempel M, Morrow M. Axillary Micrometastases and Isolated Tumor  
449 Cells Are Not an Indication for Post-mastectomy Radiotherapy in Stage 1 and 2 Breast  
450 Cancer. *Ann Surg Oncol.* 2017;24(8):2182-8.
- 451 44. Konishi T, Tanabe M, Michihata N, et al. Risk factors for arm lymphedema following breast  
452 cancer surgery: a Japanese nationwide database study of 84,022 patients. *Breast Cancer.*  
453 2023;30(1):36-45.
- 454 45. Ren Y, Kong X, Yang Q, et al. Incidence, risk factors, prevention and treatment of  
455 postmastectomy pain syndrome in breast cancer: A multicenter study. *Int J Surg.*  
456 2022;106:106937.
- 457 46. Taylor C, Correa C, Duane FK, et al. Estimating the Risks of Breast Cancer Radiotherapy:  
458 Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous  
459 Randomized Trials. *J Clin Oncol.* 2017;35(15):1641-9.
- 460 47. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after  
461 radiotherapy for breast cancer. *N Engl J Med.* 2013;368(11):987-98.
- 462 48. Su YR, Buist DS, Lee JM, et al. Performance of statistical and machine learning risk  
463 prediction models for surveillance benefits and failures in breast cancer survivors. *Cancer*  
464 *Epidemiol Biomarkers Prev.* 2023.
- 465 49. Huang X, Xu X, Xu A, et al. Exploring the most appropriate lymph node staging system for  
466 node-positive breast cancer patients and constructing corresponding survival nomograms. *J*  
467 *Cancer Res Clin Oncol.* 2023.
- 468 50. Löfgren L, Eloranta S, Krawiec K, Asterkvist A, Lönnqvist C, Sandelin K. Validation of data  
469 quality in the Swedish National Register for Breast Cancer. *BMC Public Health.*  
470 2019;19(1):495.

- 471 51. Gruber IV, Rueckert M, Kagan KO, et al. Measurement of tumour size with mammography,  
472 sonography and magnetic resonance imaging as compared to histological tumour size in  
473 primary breast cancer. *BMC Cancer*. 2013;13:328.
- 474 52. Steinhof-Radwańska K, Lorek A, Holecki M, et al. Multifocality and Multicentrality in Breast  
475 Cancer: Comparison of the Efficiency of Mammography, Contrast-Enhanced Spectral  
476 Mammography, and Magnetic Resonance Imaging in a Group of Patients with Primarily  
477 Operable Breast Cancer. *Curr Oncol*. 2021;28(5):4016-30.
- 478


(a)





### Nomogram I Prediction of $\geq 1$ macro-SLNMs



(b)


### Nomogram II Prediction of $>2$ macro-SLNMs





(a)

### Nomogram I applied to the overall study cohort



(b)

### Nomogram II applied to the overall study cohort

